NEW YORK (GenomeWeb) – Predicine announced today that it has signed a deal under which it will co-promote its next-generation sequencing-based liquid biopsy cancer diagnostics in China with Shanghai-based CloudHealth Genomics.
Under the terms of the deal, CloudHealth will provide clinical genetic testing infrastructure and sequencing capacity in China for Predicine's PrediSeq cell-free DNA NGS cancer diagnostics, which are expected to launch mid-year, as well as additional tests that are slated for commercialization in "the upcoming year," the firms said.
Additional terms of the arrangement were not disclosed.
"Liquid biopsy cancer testing is being widely adopted and implemented in America, and we hope to promote it as a standard practice in hospitals thßroughout China as part of this strategic partnership with CloudHealth," Predicine President Winston Patrick Kuo said in a statement.